House Subcommittee Examines the Drug Supply Chain | Association for Accessible Medicines
CBS News - How critics say drug companies play "games" to stave off generic competitors.
U.S. House of Representatives Energy and Commerce Health Subcommittee 12-13-17
Photo Credit: https://energycommerce.house.gov

House Subcommittee Examines the Drug Supply Chain

AAM President and CEO Chip Davis testified before the U.S. House of Representatives Energy and Commerce Health Subcommittee December 13 at its hearing, “Examining the Drug Supply Chain.” The oldest standing legislative committee in the U.S. House of Representatives, this body is vested with the broadest jurisdiction of any congressional authorizing committee.

In his testimony, Chip emphasized that the sustainability of a competitive generic market and the availability of generic medicines for patients, uninterrupted by shortages, is in jeopardy. In 1984, Congress enacted the Hatch-Waxman Act which represents a model of successful, bipartisan public policy. Over its more than 30-year history, the Act has produced a thriving and constantly-changing marketplace by balancing innovation in drug development and accelerating the availability of lower cost generic alternatives. This has important effects on public health, allowing patients to live longer, healthier lives. This balance is now threatened by three factors:

  • changing and increasingly challenging market and reimbursement frameworks;
  • the abuse of laws and regulations by bad actors; and,
  • a failure of policy to account for the unique challenges facing generic and biosimilar medicines.

Congress should: